CytRx Corporation (CYTR)

OTCMKTS: CYTR · Delayed Price · USD
0.122
-0.004 (-3.10%)
May 18, 2022 11:17 AM - Market open
Market Cap5.30M
Revenue (ttm)n/a
Net Income (ttm)-1,515.09B
Shares Out43.48M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,150
Open0.126
Previous Close0.126
Day's Range0.122 - 0.126
52-Week Range0.090 - 4.700
Beta1.89
AnalystsBuy
Price Targetn/a
Earnings DateMay 11, 2022

About CYTR

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumi...

IndustryBiotechnology
IPO DateNov 10, 1986
CEOSteven Kriegsman
Employees3
Stock ExchangeOTCMKTS
Ticker SymbolCYTR
Full Company Profile

Financial Performance

Financial Statements

News

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

6 months ago - Business Wire

CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

10 months ago - Business Wire

CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Inv...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

10 months ago - Business Wire

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other symbols:FBIOMBIOMEIPMTNB
11 months ago - PennyStocks

CytRx Comments on Quarterly Results and Year-to-Date Progress

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

1 year ago - Business Wire

CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Dis...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Highlights Orphazyme's Acceleration of Pre-Launch Activities for Arimoclomol

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Issues Statement Regarding Orphazyme’s Global Offering

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

1 year ago - Business Wire

CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomo...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted...

1 year ago - Business Wire